Mr. J. Roderick Matheson reports

MARVEL BIOSCIENCES IDENTIFIES LIQUID FORMULATIONS FOR NEURODEVELOPMENTAL DISORDERS

Marvel Biosciences Corp. and its wholly owned subsidiary, Marvel Biotechnology Inc., have identified two lead pediatric-friendly liquid formulations of its patented lead compound, MB-204.

This work was supported by a National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) grant and focused on the design of a small-volume oral liquid formulation of MB-204. This formulation is particularly important for children and adolescents with neurodevelopmental disorders, many of whom have difficulty swallowing pills or rely on feeding tubes, making standard solid oral dosage forms difficult or impractical to administer. The research focused on identifying a prototypic formulation that would ideally possess:

• Well-accepted, clinic-ready excipients;
• A high-concentration/low-volume dosing solution;
• A simple, economic manufacturing process;
• Long-term stability at room temperature;
• High oral bioavailability.

"We believe we have identified two very attractive liquid-based formulations that fit all of our criteria," commented Dr. Mark Williams, chief scientific officer of Marvel Biosciences. "Both formulations achieved higher drug levels of MB-204 in the blood of mice than our standard liquid-based formulation, which was used successfully in our depression and autism preclinical studies. We actually achieved 79- and 91-per-cent oral bioavailability (F per cent), which not only gives us a high degree of confidence that we should get meaningful drug exposures in patients in our phase I trial, but also builds additional intellectual property around MB-204. We wish to thank the NRC for their support of this project as it helps Marvel in its transition from a preclinical to a clinically focused company."

The identification of a pediatric-friendly liquid formulation is another milestone in Marvel's development pathway and expands MB-204's accessibility, particularly for its target patient populations. These advancements support accelerated regulatory engagement and clinical readiness, while additional formulation filings are expected to strengthen the company's intellectual property portfolio around novel delivery methods. Collectively, this progress Marvel's transition into a more execution-focused phase, with a clear pathway toward clinical validation and key value inflection points.

About Marvel Biosciences Corp.

Marvel Biosciences, through its wholly owned subsidiary, Marvel Biotechnology, is a Calgary-based biotechnology company developing new treatments for neurological diseases and neurodevelopmental disorders. The company's lead drug candidate, MB-204, is a novel fluorinated derivative version of istradefylline, an approved Parkinson's drug and the only adenosine A2A receptor blocker currently on the market.

Research shows that blocking the A2A receptor may help treat conditions such as autism, depression and Alzheimer's disease. Marvel is also exploring MB-204's potential in rare disorders like Rett syndrome and fragile X syndrome, aiming to bring new options to patients with few effective treatments.

We seek Safe Harbor.